The ways paved for prophylaxis against de novo hepatitis B virus infection after liver transplantation: Still many stones left unturned

YEN-HSUAN NIMEI-HWEI CHANG2021-01-042021-01-0420061397-3142https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646860506&doi=10.1111%2fj.1399-3046.2006.00494.x&partnerID=40&md5=b07e99dbd1bae115ff912aa6d71731a9https://scholars.lib.ntu.edu.tw/handle/123456789/537071[SDGs]SDG3antivirus agent; DNA vaccine; hepatitis B antibody; hepatitis B core antibody; hepatitis B surface antibody; hepatitis B vaccine; active immunization; allograft; antibody titer; disease transmission; drug efficacy; editorial; hepatitis B; Hepatitis B virus; human; immune response; infection prevention; Korea; liver disease; liver transplantation; passive immunization; postoperative infection; reinfection; Taiwan; virus infection; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B Vaccines; Humans; Immunization, Passive; Liver Transplantation; VaccinationThe ways paved for prophylaxis against de novo hepatitis B virus infection after liver transplantation: Still many stones left unturnededitorial10.1111/j.1399-3046.2006.00494.x167125952-s2.0-33646860506